proliferative diabetic retinopathy complicated with diabetic macular edema
Conditions
Interventions
Aflibercept (as gene recombinant) 2 mg (0.05 mL) is administered intravitreally three consecutive times once a month. After that, it is injected intravitreally once every 2 months, 7 times in total un
Sponsors
Tokyo Women's Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Diagnosed as diabetic retinopathy comlicated with diabetic macular edema, and detected retinal nonperfusion area by fluorescein fundus angiography examination.
Exclusion criteria
Exclusion criteria: In case of receiving intravitreal administration of anti-VEGF drug within 3 months before enrollment. When panretinal or partial retinal photocoagulation was performed for the purpose of treatment against diabetic retinopathy within 3 months before starting participation. During systemic administration of anti-VEGF drug. Pregnant women or potential patients. Patients judged inappropriate as subjects by research managers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| retinal nonperfusion area in fluorescein fundus angiography after administration of aflibercept | — |
Secondary
| Measure | Time frame |
|---|---|
| best corrected visual acuity, macular retinal thickness measured by optical coherence tomography, number of retinal neovasculature, grade of neovascularization on the optic nerve head, grade of neovascularization on the iris | — |
Countries
Japan
Contacts
Public ContactKitano Shigehiko
Tokyo Women's Medical University The department of ophthalmologyof Diabetes Center
Outcome results
None listed